Track topics on Twitter Track topics that are important to you
23andMe, Inc. is a leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company's Personal Genome Service(TM) enables individuals to gain deeper insights into their ancestry and inherited traits. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. Its Series A investors include Genentech, Inc., Google Inc. and New Enterprise Associates. More information is available at www.23andme.com.
23andMe has had a rocky road with the FDA. But now the company seems to have figured out how to work with federal regulators.
23andMe made two announcements on the same day that point towards the future of its business: it revealed it had raised $250 million in financing and released details from a long-running study into Pa...
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and 23andMe announced a collaboration to build a large, diverse cohort of both patients and control volunteers who have consented to...
23andMe has launched a study to understand the role of genetics in some of the major depressive and bipolar disorders.
(Tech Crunch) – 23andMe is best known for its $199 at-home spit-tube DNA test, but the consumer genetics company has been making strides in the last few years to get into drug development and re...
A $4 million study by the Michael J. Fox Foundation for Parkinson’s Research and 23andMe aims to see if a precision-medicine approach might work.
Once barred from giving consumers disease-related information about their DNA, 23andMe recently received approval to market such genetic tests directly to consumers—and it now has reeled in a bo...
23andMe Inc. (consumer genetics and research) raised $250mm in what appears to be its Series F growth financing round led by new investor Sequoia Capital (adds board seat). New investors Euclidean Ca...
Chronotype, or diurnal preference, refers to behavioral manifestations of the endogenous circadian system that governs preferred timing of sleep and wake. As variations in circadian timing and system ...
A phenome-wide association study of variants in genes in the Th17 and IL-17 pathway was performed using self-reported phenotypes and genetic data from 521,000 research participants of 23andMe. Results...
Many conditions affecting health are caused by a combination of environment, behaviors, and genes. While individuals can alter some factors in their lives to reduce the chances of developi...
23andMe, Inc. is a leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The co...
Cureatr is the nationâs fastest growing mobile care coordination solution for healthcare providers. By combining HIPAA-secure text messaging with workflow navigation tools to...
We have published hundreds of 23andMe, Inc. news stories on BioPortfolio along with dozens of 23andMe, Inc. Clinical Trials and PubMed Articles about 23andMe, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of 23andMe, Inc. Companies in our database. You can also find out about relevant 23andMe, Inc. Drugs and Medications on this site too.
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...